Baseline caspase activity predicts progression free survival of temsirolimus-treated head neck cancer patients
Authors:
- 1 August 2015
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (12) , 1596-1602
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft
This publication has 38 references indexed in Scilit:
- Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group TrialJournal of Clinical Oncology, 2013
- Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische OnkologieOncology, 2013
- A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancerCancer, 2013
- mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous CarcinomasClinical Cancer Research, 2012
- mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell CarcinomaCurrent Treatment Options in Oncology, 2012
- Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2009
- Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell linesCancer Chemotherapy and Pharmacology, 2007
- Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array InitiativeClinical Cancer Research, 2007
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer CellsClinical Cancer Research, 2004